Introduction
Tumour suppressor protein p53 has been shown to be involved, either directly or indirectly, in many cellular activities. It controls transcriptional activation from promoters containing its binding site (Funk et al., 1992; El-Deiry et al., 1992) and the translation of its own mRNA (Mosner et al., 1995) . p53 also has direct eect on DNA replication in embryonic cells (Cox et al., 1995) . It is involved in the control of cell cycle (Levine et al., 1991) and apoptosis (Lowe et al., 1993) .
Of all these activities, the regulation of transcription by p53 has been most extensively studied. p53 binds speci®cally to DNA similar or identical to the consensus 5'RRRC(A/T)(A/T)GYYYN 0 ± 13 RRRC(A/ T)(A/T)GYYY3' . There are several genes containing this type of p53 binding site in their promoters and are therefore regulated by changes of levels of p53. These include p21 WAF1/CIP1 (ElDeiry et al., 1993) , mdm2 (Barak et al., 1993) , gadd45 (Kastan et al., 1992) , bax (Miyashita and Reed, 1995) and IGF BP-3 (Buckbinder et al., 1995) .
Human p53 protein, which contains 393 amino acids, is able to form tetramers due to the protein-protein interactions. An area responsible for tetramerization is located between amino acids 323 and 355 (Clore et al., 1994; Wang et al., 1994) . It has been shown that oligomeric p53 is more active in transcription, but monomeric forms of p53 are also able to activate promoters containing p53 binding site (Tarunina and Jenkins, 1993; Wang et al., 1993; Crook et al., 1994; Sang et al., 1994; Pellegata et al., 1995) . Although monomeric p53 does not form oligomers in solution, it still binds DNA co-operatively as a tetramer (Balagurumoorthy et al., 1995) .
In human tumours p53 protein has been often mutated. Because it is expressed from both alleles, the overall content of intracellular p53 can be either wildtype (wt), mixture of wt and mutant p53 or mutant p53 only (when both alleles are mutated or one allele is deleted). Although the tumour-associated mutations found cover the whole molecule, certain`hot spots' for mutations have been described (Levine et al., 1991) . These point mutants have lost their DNA-binding activity. In the case of coexpression of mutant and wt p53 it has been shown that mutant p53 can drive wt p53 to mutant conformation (Milner and Medcalf, 1991) and the transactivation function of wt p53 is inhibited by mutant p53 . It is generally believed that the mechanism behind this eect is that mutant p53 proteins form heterooligomers with wt proteins, which are less active in transcriptional activation than homooligomers of wt protein.
In this paper we show that, in addition of heterooligomerization, other mechanisms of repression of p53 function can also be involved in cells expressing both wild-type and mutant p53. We show that (1) the transcativation function of p53 protein unable to oligomerize is also suppressed by tumour-associated mutants of p53; (2) This eect is speci®c to p53-dependent promoters and requires the presence of either C-or N-terminus of the mutant protein; (3) Tumour-associated point mutants are able to inhibit the growth suppressing function of monomeric p53. Our data allow to propose the existence of p53-speci®c transcriptional coactivator(s) needed for p53 to activate the p53-speci®c promoters and mediate its biological eects.
Results

Tumour-associated point mutants of p53 can inhibit the transactivation function of monomeric p53
Mutant p53 has a dominant negative eect over the wt protein. This is thought to be mediated through the heterooligomerization between wt and mutant p53. In that case, the monomeric p53 would be insensitive to mutant protein, because heterooligomers cannot form. To test this hypothesis, we carried out series of transfections ( Figure 2 ). Every transfection contained 1.2 mg of pBS-CON-CAT as a reporter and 250 ng of D324 ± 355 as a transactivator (except the ®rst column, which represents transfection, containing only the reporter). Cells were lysed after 24 h and CAT assays were performed. Cotransfection with dierent point mutants clearly inhibited the activity of D324 ± 355 (Figure 2a ). To get more insight into the nature of this inhibition, we made several deletions based on the Trp248 mutant (Figure 1) . When either N-or Cterminus are deleted, the mutant can still inhibit the transcriptional activity of the D324 ± 355 ( Figure 2B ). When both of these termini are absent (40-361Trp), the mutant is not able to repress the D324 ± 355 activity. Neither of the point mutants used had any transcriptional activation function by themselves (data not shown).
Repression phenomenon is not dependent on the nature of the p53 binding site
Reporter plasmid, used in the experiments described in Figures 2a and b , contains a synthetic p53 binding site in front of the adenovirus E2 promoter. This binding site, named CON, binds p53 very eciently and does not occur in natural promoters. To test our ®nding in more physiological context, we did the same kind of experiments using a plasmid pWWP-CAT, containing 2.4 kb fragment from human WAF1 promoter in front of the CAT gene (El-Deiry et al., 1993) . Figure 3 shows the results of three independent experiments. Every transfection contained 1.2 mg of pWWP-CAT as a reporter and 5 mg of pCG-D324 ± 355 as a transactivator (except the ®rst column, were only the reporter plasmid was used for transfection). Note that we used much higher amount of pCG-D324 ± 355 than in previous experiment in order to get suciently high CAT activity. This was probably due to weaker binding of p53 to its binding site in WAF1 promoter as compared to the CON site. Dierent point mutants repress the transactivation function of the D324 ± 355 with the same pattern as in the Figure 2a and b ± only the 40-361Trp mutant was not able to inhibit the 1.2 mg of CAT reporter plasmid was included in every transfection. Columns indicate average CAT activity from three independent experiments. CAT activity from cotransfection with empty pCG vector is taken as 1
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p53-independent transcription is not aected by point mutants
Wt p53 can, at least when overexpressed, inhibit many dierent promoters. Though there are no hints in the literature that tumour-associated point mutants can do the same, we tested their ability to inhibit the CMV promoter. This is a strong eukaryotic promoter, containing no p53 binding sites. A plasmid, containing b-galactosidase gene under the control of CMV promoter was included in every transfection. After the lysis of the cells half of lysate was used to determine the b-galactosidase activity. As the Figure  4 shows, tumour-associated point mutants do not aect the b-galactosidase activity. Therefore, the inhibitory eect of the point mutants is restricted to the promoters containing p53 binding site.
Coexpression of point mutants with D324 ± 355 does not alter the quantity or localization of the latter
One possibility to explain why the point mutants inhibit the activity of the D324 ± 355, is that their own expression may saturate some stage of the gene expression and therefore the expression of the D324 ± 355 decreases. To control this, we analysed by Western blotting the lysates from cells contransfected with D324 ± 355 and dierent point mutants ( Figure 5 ). No remarkable dierences in the amount of D324 ± 355 can be observed between dierent transfections. Therefore, the dierences in the transcriptional inhibition function between DN39Trp and 40-361Trp or between DC362Trp and 40-361Trp can not be explained by dierent expression levels of D324 ± 355. Note that DC362Trp and D324 ± 355 comigrate as a one band. In order to function as transcriptional activator p53 must be localized in cell nucleus. It could be possible that expression of the point mutants will abolish the nuclear localization of the D324 ± 355. To control this we cotransfected the cells with pCG-D324 ± 355 and with plasmids encoding deletions of point mutants.
Immuno¯uorescence analysis with dierent antibodies detected only the D324 ± 355 protein in cells expressing Figure 3 Inhibition of transactivation occurs also from natural promoters. Cells were cotransfected with D324 ± 355 (5 mg) p53 expression vector and with expression plasmid carrying point mutant p53 cDNA, deletions of Trp248 mutant or with empty pCG plasmid (5 mg). 1.2 mg of pWWP-CAT reporter plasmid was included in every transfection. Columns indicate average CAT activity from three independent experiments. CAT activity from cotransfection with empty pCG vector is taken as 1 Figure 4 Point mutant p53 proteins do not inhibit p53-independent transcription. All transfections, were D324 ± 355 was used as activator, contained 0.5 mg of b-galactosidase reporter plasmid with CMV promoter. Columns indicate average bgalactosidase activity from three independent experiments. Activity from cotransfection with empty pCG vector is taken as 1 Figure 5 Coexpression with dierent deletion mutants does not alter the amount of D324 ± 355. Cells were cotransfected with 5 mg pCG-D324 ± 355 and with 5 mg of the constructs indicated. After 24 h cells were lysed and the Western blot was carried out. p53 was detected with monoclonal antibody pAb240 two forms of p53. As shown in Figure 6 , the D324 ± 355 is nuclear in all cases examined and the inability to localize in nucleus is not the reason for transcriptional inhibition.
D324 ± 355 does not form heterooligomers with p53 point mutants
To show that protein D324 ± 355 is not able to give oligomers in the expression conditions used here we carried out crosslinking experiments. Cells cotransfected with D324 ± 355 and mutants DN39Trp, DC362Trp or 40-361Trp were lysed, crosslinked with glutaraldehyde, devided between two equally loaded gels, electrophoresed and blotted to nitrocellulose. Using dierent primary antibodies we were able to show that even in the case of coexpression with point mutant the D324 ± 355 remains monomeric in solution (Figure 7 ). From this we conclude that transcriptional inhibition by DN39Trp and DC362Trp is not due to heterooligomerization with D324 ± 355.
Point mutants can inhibit the growth suppression function of monomeric p53
In order to clarify the relevance of our results in more biological assay, we tested the in¯uence of point mutants to the growth suppression activity of D324 ± 355. It is reported that monomeric p53 expresses clear growth suppressing activity, although less than wt protein does (Shaulian et al., 1993; Thomas et al., 1996) . We performed growth suppression assay and results of that are described in Figure 8 . Wt p53 inhibited colony formation almost entirely and D324 ± 355 reduced the number of colonies approximately 50% as compared to the transfections with the resistance marker (pBabe Puro) only. When Trp248, DN39Trp or DC362Trp were added to the transfection mixture, they inhibited the growth suppressing activity of the monomer. The same mutants did not aect notably the colony formation activity, when expressed alone with pBabe Puro (data not shown). Because the 40-361Trp has itself the ability to reduce the colony number (data not shown), its eect to the activity of the monomer could not be examined.
Discussion
Transcriptional activation is the best studied biochemical function of p53. p53 mediates signals for cell cycle arrest and apoptosis by activating transcription from many dierent promoters (Kastan et al., 1992; El-Deiry et al., 1993; Barak et al., 1993; Miyashita and Reed, 1995; Buckbinder et al., 1995) . Tumour hot-spot mutations occur at residues essential for DNA-binding and therefore inactivate the transcriptional activation function of p53 . Because most of wt p53 exists in tetrameric form, heterooligomers between wt and mutant p53 are present in tumours. Inactivation of wt p53 by heterooligomerization with mutant protein is thought to be the mechanism of inhibition of wt p53 activities by mutant p53, transcriptional activation included. However, we present here experimental evidence showing that heterooligomerization is not the only way how mutant p53 can inhibit wt p53
Figure 6 D324 ± 355 is nuclear when coexpressed with point mutants. Cells were transfected with the 5 mg pCG-DN39Trp (a), pCG-DC362Trp (b) or pCG-40-361 Trp (c). 5 mg pCG-D324 ± 355 was included in all transfections. In a and c cells were stained with antibody B17, which reacts with p53 amino acids 16 ± 25 (epitope deleted in DN39Trp and in 40-361Trp). In b cells were stained with antibody pAb421, which reacts with p53 amino acids 372 ± 382 (epitope deleted in DC362Trp). With these antibodies only the D324 ± 355 is detected. Transfection eciency was approximately 25% transactivation function. Mutant forms of p53 can also inhibit the transactivation function of monomeric p53 (D324 ± 355; Figures 2 and 3, see also Subler et al., 1994) . When both N-and C-termini are deleted from mutant p53, it is not able to inhibit D324 ± 355 (Figures  2 and 3) . The proof that point mutants can also aect the biological activity of the monomeric p53 comes from growth suppression assay (Figure 8 ). Expressing point mutants together with D324 ± 355 clearly inhibited the growth suppression function of the latter. Taken together, our data suggest that in addition to heterooligomerization also other mechanisms can stay behind the inhibition of wt p53 by its mutant forms.
As a transcriptional activator p53 needs to bind several basic transcription factors. Indeed, interactions between p53 and components of TFIID and TFIIH complexes have been described (Liu et al., 1993; Lu and Levine, 1995; Martin et al., 1993; Seto et al., 1992; Thut et al., 1995; Truant et al., 1993; Xiao et al., 1994) . It could be possible that mutant p53 binds some of these basic factors and depletes the cells from them. Our results show that this is not the case: overexpression of mutant p53 does not alter the expression from CMV promoter (Figure 4) , activity of which is also dependent on general transcription factors. Overexpression of mutant p53 has in¯uence only to p53-dependent promoter and this is not caused by alterations in D324 ± 355 expression or localization (Figures 5 and 6 ). From these data we propose that mutant p53 interacts with factor(s) speci®cally needed for p53-dependent transactivation but not for transcription in general.
Most tumour-associated mutations in p53 are clustered in the central part of the molecule and they inactivate the DNA binding function of the p53. Some of these mutations aect the overall conformation of central part of the molecule (Gannon et al., 1990) , whereas conformations of the N-and C-termini are most probably not changed. Therefore, the modifying enzymes and cofactors targeted to the termini of wt molecule are also able to bind to mutant p53. If the mutant form of p53 is expressed at high level, it may deplete cells from cofactors, necessary for p53 to activate transcription. The transactivating function of p53 can be allosterically modi®ed by dierent factors. It has been shown that DNA-binding of wt p53 can be enhanced by speci®c peptides and antibodies against the C-terminus (Hupp et al., 1992 . The c-Abl and WT-1 are cellular proteins binding wt p53 and activating its transactivation function (Goga et al., 1995; Maheswaran et al., 1993 Maheswaran et al., , 1995 Yuan et al., 1996) . Recently, new activators of p53 were identi®ed, including ref-1 (Jayaraman et al., 1997), HMG-1 (Jayaraman et al., 1998), p33
ING1 (Garkavtsev et al., 1998) and BRCA1 (Ouchi et al., 1998; Zhang et al., 1998) . It is not known, whether they can interact with point mutants of p53 or with monomeric p53. Therefore we have no clues to speculate, could one of these activators be depleted from cells by mutant p53 in our experiments. Necessity of coactivator for p53-dependent transactivation is shown only for p33
ING1
. Whether the others are also necessary for p53-dependent transactivation or have only additive eects needs to be clari®ed in future.
Two explanations can be proposed to the fact that 40-361 Trp cannot inhibit D324 ± 355 mediated transactivation. First, the deletions of both ends in 40-361 Trp may aect the overall conformation of the molecule making it unable to bind the speci®c cofactor. The other explanation comes from hypothesis according to which N-and C-termini are close to each other in 3-dimensional structure. They could generate a binding site for this proposed cofactor and only the deletions of both of them abolish the binding of the cofactor.
Alternatively, wt p53 may need a speci®c modification for its activity rather than binding to a speci®c cofactor. Indeed, many kinases have been shown to phosphorylate p53. Casein kinase II and protein kinase C phosphorylate the C-terminus of p53 and probably unmask the DNA-binding function of p53 (Baudier et al., 1992; Takenaka et al., 1995; Meek et al., 1990) . S and G 2 /M cdks can also activate p53 and even in¯uence its binding site speci®city (Wang and Prives, 1995) . In addition to C-terminal phosphorylation sites, many serine residues which can be phosphorylated are clustered in N-terminus (Milne et al., 1992; Knippchild et al., 1996; Lees-Miller et al., 1992) . Replacing two or more of these serine residues with alanines diminishes p53 transactivating abilities (Mayr et al., 1995) . It is also known that wt p53 puri®ed from bacteria does not bind DNA, although p53 produced in insect or mammalian cells does (Hupp et al., 1992; Wolkowicz et al., 1995) . Possible explanation for this is that wt p53 from bacteria does not have necessary modi®cations. If p53 needs to be phosphorylated in order to activate transcription, the inhibitory eect of point mutants to D324 ± 355 mediated transcription may relay on the saturation of the modifying enzymes. Because point mutants are expressed in high amounts they could titrate the D324 ± 355 out. Following this line two or more modi®cations are needed for transactivation by p53 ± at least one for N-and the other for C-terminus. If even one of these possible modifying enzymes is depleted from wt p53, the p53 cannot activate transcription. Only in the case of 40-361 Trp the D324-355 retains its activity, because this deletion of point mutant is not able to bind any modifying enzyme.
Materials and methods
Plasmid constructs and antibodies
CAT reporter plasmid pBS-CON-CAT contains the XhoI ± XbaI fragment from plasmid E2-100 CAT (Tarunina and Jenkins, 1993) 
in pBluescript KS
7 . It has p53 consensus DNA-binding site CON (Funk et al., 1992) and modi®ed adenovirus E2 promoter in front of CAT gene. pWWP-CAT contains 2.4 kb region from human WAF1 promoter (E1- Deiry et al., 1993) in front of the CAT gene and was a generous gift from Dr Bert Vogelstein. Plasmid pON 260 (Spaete and Mocarski, 1985) was used to express bgalactosidase from CMV promoter. pBabe Puro contains the puromycin resistance gene under the control of SV40 promoter between the Murine Leukemia Virus Long Terminal Repeats (Morgenstern and Land, 1990) . All p53 cDNA-s were cloned between XbaI and BglII sites of eukaryotic expression vector pCG (Tanaka and Herr, 1990) . pCG-Hwt, pCG-His175, pCG-Ala143 and pCGTrp248 contain human wt, 175 Arg?His, 143 Val?Ala and 248 Arg?Trp point mutation p53 cDNAs, respectively. For creating pCG-D324 ± 355, two regions of wt p53 cDNA were ampli®ed: one between codons 1 and 323 and another between codons 356 and 393. Resulting cDNA-s were linked in frame to each other from PstI site designed into PCR primers. Half of PstI site (CAG) encodes an extra amino acid (Glu) between these two regions. This cDNA was inserted between XbaI and BglII sites of pCG vector and encodes p53 protein with amino acids 324 ± 355 deleted. DN39Trp encodes p53 protein with deletion of the ®rst 39 amino acids and 248 Arg?Trp mutation. DC362Trp encodes truncated protein with stop codon at position 362 and 248 Arg?Trp mutation. 40-361Trp encodes mutant p53 starting from amino acid 40, containing a stop codon at the position 362 and amino acid substitution at position 248. Schematic presentation of p53 proteins is shown on Figure 1 . Empty pCG does not contain any insert ± the poly (A) signal follows directly the CMV promoter. p53 was detected with monoclonal antibodies pAb421 (Harlow et al., 1981 , epitope between amino acids 372 ± 381), pAb1801 (Banks et al., 1986 , epitope between amino acids 46 ± 55), pAb240 (Gannon et al., 1990 , epitope between amino acids 210 ± 214) and B17 (Legros et al., 1994 , epitope between amino acids 16 ± 25). The last was generous gift from Dr Thierry Soussi.
Cell culture and transfection
Saos2 cells were cultured in Iscove's modi®ed Eagle's medium (IMEM) supplemented with 10% foetal calf serum. Cells were maintained at 378C in humidi®ed 5% CO 2 atmosphere. Cells were transfected by electroporation method as follows: 5 ± 10 million cells were collected from 70% con¯uent cell dishes and suspended in IMEM containing 5 mM Na-BES (N,N-bis[2-Hydroxyethyl]-2-aminoethanesulfonic acid). 50 mg sonicated salmon sperm DNA, expression and reporter plasmids were added to 250 ml of cell suspension and the cells were transfected using`Invitogene' electroporator (settings 1000 mF and 210 V). After electroporation, cells were resuspended in IMEM and transferred to growth conditions on 6 or 10 cm diameter cell culture dishes.
CAT and b-galactosidase assay 1.2 mg of pBS-CON-CAT or pWWP-CAT and 0.5 mg of pON 260 reporter plasmids were used per transfection. Cells were collected 24 h after transfection and lysed by three cycles of rapid freezing and thawing. All lysates were normalised before CAT and b-galactosidase reaction according to total amount of protein (Bradford, 1976) . Enzyme reactions were performed at standard conditions (Sambrook et al., 1989) . For CAT assay thin layer chromatography plates were exposed to PhosphorImager and data were quantitated with ImageQuaNT software.
Western blotting and oligomerisation assay
For Western blotting cells were lysed 24 h after transfection in 30 ml IP buer (500 mM NaCl, 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% NP-40, 0.02% NaN 3 , 0.027 mTIU/ml aprotinin, 0.1 mM PMSF) for 30 min in ice. Cell debris were removed by centrifugation at 12 000 r.p.m. for 5 min, 30 ml SDS loading buer (50 mM TrisHCl pH 6.8; 100 mM DTT; 2% SDS; 0.1% bromophenol blue; 10% glycerol) was added to lysate and it was boiled for 10 min. Lysate was separated by SDS ± PAGE in 12% gel. Proteins were transferred to nitrocellulose ®lter. Free surface of the ®lter was blocked for 10 min at room temperature (RT) with 1% non-fat milk powder in PBS+0.05% Tween 20. Filter was incubated with monoclonal antibody pAb240 in blocking solution for 2 h at RT. After washing with PBS+Tween 20 ®lter was incubated for 2 h at RT with goat antibody against mouse Ig conjugated with alkaline phosphatase.
For oligomerization assay cells were transfected with 2 mg of expression plasmid and lysed 24 h later in 150 ml IP buer on ice for 30 min. Each lysate was divided between ®ve tubes and glutaraldehyde was added to ®nal concentration of 0; 0.003; 0.01; 0.03 or 0.1%. After incubation for 15 min on ice, equal volumes of 26SDS loading buer were added. Samples were boiled for 10 min, separated in 6% SDS-polyacrylamide gel and transferred to nitrocellulose ®lter. p53 was detected with antibodies pAb1801, pAb421, pAb240 and rabbit antimouse Ig secondary antibody conjugated with alkaline phosphatase (`LabAs', Estonia).
Immuno¯uoresence
Cells, growing on cover slips, were ®xed at 7208C in acetone/methanol (1:1). Primary antibodies were diluted in 1% BSA in PBS and incubated at RT for 1 h. After washing three times with PBS cover slips were incubated with goat anti-mouse antibody conjugated with FITC (LabAs). Cells were visualized and photographed using Olympus AH-2 microscope.
Cell growth suppression assay
Saos-2 cells were transfected with pBabe Puro, pCG-D324 ± 355 and with indicated plasmids (Figure 8 ). Twenty-four hours after transfection the cells were replated with equal densities (1.5610 5 cells per 100 mm plate). Forty-eight hours after transfection the fresh medium containing puromycin (1 mg/ml) was added. Cells were grown in the presence of puromycin for 1 week and then 1 week without the selection. After that cells were ®xed in 0.05% glutaraldehyde in PBS, stained with Coomassie R-250, and the colonies were counted.
